GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ventyx Biosciences Inc (NAS:VTYX) » Definitions » EV-to-EBIT

Ventyx Biosciences (Ventyx Biosciences) EV-to-EBIT : -0.35 (As of May. 10, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ventyx Biosciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ventyx Biosciences's Enterprise Value is $73.30 Mil. Ventyx Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-207.99 Mil. Therefore, Ventyx Biosciences's EV-to-EBIT for today is -0.35.

The historical rank and industry rank for Ventyx Biosciences's EV-to-EBIT or its related term are showing as below:

VTYX' s EV-to-EBIT Range Over the Past 10 Years
Min: -39.48   Med: 0   Max: 1.12
Current: -0.35

During the past 5 years, the highest EV-to-EBIT of Ventyx Biosciences was 1.12. The lowest was -39.48. And the median was 0.00.

VTYX's EV-to-EBIT is ranked worse than
100% of 431 companies
in the Biotechnology industry
Industry Median: 9.23 vs VTYX: -0.35

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Ventyx Biosciences's Enterprise Value for the quarter that ended in Dec. 2023 was $-93.39 Mil. Ventyx Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-207.99 Mil. Ventyx Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 222.71%.


Ventyx Biosciences EV-to-EBIT Historical Data

The historical data trend for Ventyx Biosciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ventyx Biosciences EV-to-EBIT Chart

Ventyx Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - -8.88 -13.72 0.45

Ventyx Biosciences Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.72 -11.88 -9.40 -8.97 0.45

Competitive Comparison of Ventyx Biosciences's EV-to-EBIT

For the Biotechnology subindustry, Ventyx Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ventyx Biosciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ventyx Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ventyx Biosciences's EV-to-EBIT falls into.



Ventyx Biosciences EV-to-EBIT Calculation

Ventyx Biosciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=73.302/-207.994
=-0.35

Ventyx Biosciences's current Enterprise Value is $73.30 Mil.
Ventyx Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-207.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ventyx Biosciences  (NAS:VTYX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Ventyx Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-207.994/-93.393423
=222.71 %

Ventyx Biosciences's Enterprise Value for the quarter that ended in Dec. 2023 was $-93.39 Mil.
Ventyx Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-207.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ventyx Biosciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Ventyx Biosciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Ventyx Biosciences (Ventyx Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
662 Encinitas Boulevard, Suite 250, Encinitas, CA, USA, 92024
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Executives
Raju Mohan director, officer: Chief Executive Officer C/O VENTYX BIOSCINECES, INC., 332 ENCINITAS BLVD., SUITE 200, ENCINITAS CA 92024
John Nuss officer: Chief Scientific Officer C/O VENTYX BIOSCIENCES, INC., 332 ENCINITAS BLVD. SUITE 200, ENCINITAS CA 92024
Christopher W Krueger officer: Chief Business Officer C/O ARDEA BIOSCIENCES INC, 2131 PALOMAR AIRPORT ROAD SUITE 300, CARLSBAD CA 92011
Nsv Partners Iii Lp 10 percent owner 500 WEST PUTNAM AVE, SUITE 400, GREENWICH CT 06830
Somu Subramaniam director, 10 percent owner C/O ICAD INC, 98 SPIT BROOK ROAD SUITE 100, NASHUA NH 03062
Martin Auster officer: Chief Financial Officer C/O VENTYX BIOSCIENCES, INC., 662 ENCINITAS BLVD. STE 250, ENCINITAS CA 92024
William J. Sandborn officer: See Remarks C/O VENTYX BIOSCIENCES, INC., 662 ENCINITAS BLVD. STE 250, ENCINITAS CA 92024
Sheila Gujrathi director 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
William Richard White director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Onaiza Cadoret-manier director 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Allison Hulme director C/O SOPHIRIS BIO INC., 1258 PROSPECT ST, LA JOLLA CA 92037
Venbio Global Strategic Fund Iii, L.p. 10 percent owner, other: See Remarks 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Aaron Royston director, 10 percent owner 200 CARDINAL WAY, 2ND FLOOR, REDWOOD CITY CA 94063
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116